Mangoceuticals Inc. has announced amendments to its corporate bylaws, specifically establishing the terms for its 6% Series B Convertible Cumulative Preferred Stock. The amendments designate 1,000,000 shares of Series B Preferred Stock, which will offer dividend rights at a rate of 6% per annum on the stated value, payable quarterly, and conversion rights into common stock. The changes will take effect starting September 30, 2025, marking a significant update to the company's financial structure.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-018467), on July 10, 2025, and is solely responsible for the information contained therein.